Piśmiennictwo

1. Feinstein D, Rapaport S. Acquired inhibitors of blood coagulation. Prog Hemost Thromb 1972; 1: 75-95.

2. Harris EN. Syndrome of the black swan. Br J Rheumatol 1987; 26: 324-326.

3. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum 1999; 42: 1309-1311.

4. Myiakis S, Lockshin MD, Atsumi D. International consensus statement on an update of the preliminary classification criteria for antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.

5. Tripodi A, de Groot PG, Pengo V. Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment. J Intern Med 2011; 270: 110-122.

6. Musiał J, Swadźba J, Jankowski M, et al. Thrombin generation measured ex vivo following microvascular injury is increased in SLE patients with antiphospholipid-protein antibodies. Thromb Haemost 1997; 78: 1173-1177.

7. Cerevera R, Piette UC, Font J, et al. Antiphospholipid syndrome. Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1.000 patients. Arthritis Rheum 2002; 46: 1019-1027.

8. Galli M, Luciani D, Bertolini G, et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101: 1827-1832.

9. Swadźba J, Iwaniec T, Szczeklik A, et al. Revised classification criteria for antiphospholipid syndrome and the thrombotic risk in patients with autoimmune diseases. J Thromb Haemost 2007; 5: 1883-1889.

10. Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome.
J Thromb Haemost 2010; 8: 237-242.

11. Płazak W, Gryga K, Milewski M, et al. Association of heart structure and function abnormalities with laboratory findings in patients with systemic lupus erythematosus. Lupus 2011; 20: 936-944.

12. Cefle A, Inanc M, Sayarlioglu M, et al. Pulmonary hypertension in systemic lupus erythematosus: relationship with antiphospholipid antibodies and severe disease outcome. Rheumatol Int 2011; 31(2): 183-189.

13. Hasegawa EM, Caleiro MT, Fuller R, et al. The frequency of anti-beta2-glycoprotein I antibodies is low and these antibodies are associated with pulmonary hypertension in mixed connective tissue disease. Lupus 2009; 18: 618-621.

14. Zoller B, Li X, Sundquist J, et al. Pisk of pulmonary emboliom in patients with autoimmune disorders: a nationwide follow-up Study from Sweden. Lancet 2012; 379: 244-249.

15. Petri M. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Thromb Res 2004; 114: 593-595.

16. Dougados M, Betteridge N, Burmester GR, et al. EULAR standarised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis 2004; 63: 1172-1176.

17. Avina-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008; 59: 1690-1697.

18. Sattar N, McCarey DW, Capell H, et al. Explaining how „how-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108: 2957-2963.

19. Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999; 340: 115-126.

20. Aubry MC, Maradit-KremersH, Reinalda MS, et al. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J Rheumatol 2007; 34: 937-942.

21. Maradit-Kremers H, Nicola PJ, Crowson CS, et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005; 52: 722-732.

22. Goodson NJ, Symmonds DP, Scott DG, et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based incaption cohort. Arthritis Rheum 2005; 52: 2293-2299.

23. Wallberg-Jonsson S, Johansson H, Ohman ML, et al. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A rettrospective cohort study from disease onset. J Rheumatol 1999; 26: 2562-2571.

24. Peters M, Symmonds D, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69: 325-331.

25. Niżankowski R, Pruszczyk P, Torbicki A, et al. Żylna choroba zakrzepowo-zatorowa. [W:] Szczeklik A (red.), Choroby wewnętrzne. Stan wiedzy na rok 2010. Medycyna Praktyczna, Kraków 2010: 454-488.

26. Płazak W, Pasowicz M, Kostkiewicz M, et al. Influence of chronic inflammation and autoimmunity on coronary calcifications and myocardial pefusion defects in systemic lupus erythematosus patients. Inflammation Research 2011; 60: 973-980.

27. Uebleis C, Becker A, Griesshammer I, et al. Stable coronary artery disease: prognostic value of myocardial perfusion SPECT in relation to coronary calcium scoring – long-term follow-up. Radiology 2009; 252: 682-690.

28. Haas C. Pulmonary hypertension associated with systemic lupus erythematosus. Bull Acad Natl Med 2004; 188: 985-97.

29. Giron-Gonzales JA, Garcia del Rio E, Rodriguez C, et al. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol 2004; 31: 1560-1567.

30. Wahl DG, Bounameaux H, de Moerloose P, et al. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis. Arch Intern Med 2000; 160: 2042-2048.

31. Płońska E, Ostanek L, Przepiera-Będzak H, et al. Reumatologia. [W:] Płońska-Gościniak E (red.), Interna w obrazach echo. Medical Tribune 2010: 33-46.